High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
About this item
Full title
Author / Creator
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
The choice of therapy in patients withdrawing from natalizumab treatment is still an open question and neurologists need strategies to manage this group of patients. The aim of this study is to evaluate if alemtuzumab is able to control the disease when used in patient who have stopped natalizumab.
Methods
16 patients stopped...
Alternative Titles
Full title
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5447551
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5447551
Other Identifiers
ISSN
2193-8253
E-ISSN
2193-6536
DOI
10.1007/s40120-016-0058-0
